

# Proof-of-concept study for liver-directed miQURE technology in a dyslipidemic mouse model

Vanessa Zancanella, Astrid Vallès, Jolanda M.P. Liefhebber, Lieke Paerels, Carlos Vendrell Tornero, Hendrina Wattimury, Tom van der Zon, Kristel van Rooijen, Monika Golinska, Tamar Grevelink, Erich Ehlert, Elsbet Jantine Pieterman, Nanda Keijzer, Hans Marinus Gerardus Princen, Geurt Stokman, and Ying Poi Liu

**Correspondence:** [y.poiliu@uniquire.com](mailto:y.poiliu@uniquire.com)  
<https://doi.org/10.1016/j.omtn.2024.102189>

(Molecular Therapy: Nucleic Acids 32, 454–467; June 2023)

In the originally published version of this article, Table 2 was found to contain two minor errors: (1) one data point was accidentally duplicated, and (2) for one data point a decimal is missing. For the *Moderate-high dose rAAV5-miAngE + statin* group, the correct value for mean (SD) ALT activity, week 16, should read  $155.7 \pm 165.2$  (instead of  $355.8 \pm 366.2$ ). For the *rAAV5-miSCR* group, the correct value for mean (SD) AST activity, week 12, should read  $144.0 \pm 30.3$  (i.e., including decimal “0”).

These errors have been corrected in the article online, and the authors apologize for any confusion this may have caused.

